Pbmc Proliferation Assay
Pbmc Proliferation Assay - Related Videos
02:46
An In Vitro Assay for Evaluating the Immunomodulatory Impact of Monocytes on Leukocyte Proliferation
0 Views •
2025
This video demonstrates an in vitro assay to explore the immunomodulatory influence of mesenchymal stem cells (MSCs) on effector T cell proliferation. The assay includes co-culturing MSCs with PBMCs to induce the monocyte population to acquire an immunomodulatory phenotype, leading to the secretion of interleukin-10 (IL-10). Following incubation with activated CD4+ T cells, the induced monocytes effectively suppress T cell proliferation.
02:26
A Technique to Generate a Human PBMC-Engrafted Humanized Xenograft Mouse Model
0 Views •
2025
This video demonstrates an assay to generate a humanized xenograft mouse model. An immunocompromised mouse is injected with cyclophosphamide to cause immune cell depletion. Patient-derived tumor cells mixed with human peripheral blood mononuclear cells (PBMCs) in a hydrogel are subcutaneously injected into the mouse, forming a tumor with infiltrating T cells.
03:48
Choroid Sprouting Assay to Study Ocular Microvascular Proliferation Ex Vivo
0 Views •
2025
This video demonstrates the development of an ex vivo model of choroidal sprouting to study ocular microvascular angiogenesis. The assay involves culturing mouse eye explants containing the choroid tissue attached to the sclera and retinal pigment epithelium under specific conditions that promote choroidal microvascular sprouting.
03:59
Bromodeoxyuridine Pulse Labelling Assay: A Technique to Measure Cell Proliferation
0 Views •
2023
The video describes the stepwise pulse labeling assay of mammalian cells with bromodeoxyuridine (BrdU) for measuring cell proliferation. The BrdU uptake permits the temporal tracking of cells that were in the synthesis phase at a specific point in time, without requiring the cells to be synchronized.
05:16
A Vaccine-Pulsed Dendritic Cell-Based In Vitro Assay to Induce Lymphocyte Proliferation
0 Views •
2025
This video demonstrates a monocyte-derived dendritic cell, MoDC-based assay to measure the immunogenicity of commercially available vaccines. MoDC assays investigate dendritic cell responses to antigens, pathogens, or treatments and can provide insights into immune responses, vaccine development, and immunotherapy research.
FAQs
After PBMCs encounter a mitogen, antigen, or another test condition, responsive cells activate and divide, increasing the cell population. The assay captures this change indirectly through DNA synthesis, dilution of a cell-tracking dye, or metabolic activity. Comparing stimulated and test-condition responses helps determine whether immune cells have been activated, suppressed, or otherwise affected.
The stimulus determines what type of response the experiment examines. Mitogens provide a broad activation condition, whereas antigens are used to evaluate responses directed toward a particular immune trigger. Other test conditions can reveal immunosuppressive effects or potential toxicity. Selecting among these inputs therefore links proliferation results to general activation, antigen-specific immunity, or treatment-related effects.
DNA-synthesis measurements indicate that cells have entered a proliferative state, while cell-tracking dye dilution follows divisions through changes in cellular labeling. Metabolic readouts estimate activity associated with the responding cell population. These approaches quantify the outcome through different biological signals, so the selected readout should match whether the study emphasizes division, cell tracking, or cellular activity.
PBMCs contain lymphocytes and monocytes, so the measured response reflects activity within a mixed peripheral blood cell population rather than an isolated cell type. This composition provides a broader view of cellular immune behavior, but it also means that an overall proliferation result should be interpreted in the context of the combined PBMC response and the applied stimulus.
A typical workflow uses isolated PBMCs, exposes them to a mitogen, antigen, or other defined test condition, and then measures the resulting proliferative response. The final assessment may rely on DNA synthesis, cell-tracking dye dilution, or a metabolic readout. This sequence connects the experimental condition with a quantifiable change in immune-cell growth.
Researchers apply this assay when they need to characterize cellular immunity or determine how immune cells respond to a defined stimulus or treatment. It can support studies of infection, vaccination, autoimmune disease, cancer, and therapeutic development. The same general approach can also examine immunosuppressive effects and potential drug toxicity by comparing responses across test conditions.
In therapeutic studies, changes in PBMC proliferation can indicate whether a candidate treatment alters immune-cell activation, produces immunosuppressive effects, or shows potential toxicity. Because responses are measured after exposure to a defined test condition, investigators can compare cellular outcomes across treatments. These findings help characterize how a therapy may influence cellular immunity during development.